FDA Denies Approval for Patisiran in ATTR Cardiomyopathy

In a complete response letter, the FDA said the clinical meaningfulness of patisiran's effects in cardiomyopathy of ATTR amyloidosis are not established, despite good reviews from an advisory panel.
Medscape Medical News